Amyotrophic Lateral Sclerosis (ALS), or Motor Neurone Disease (MND), is a progressive neurodegenerative disorder affecting upper and lower motor neurones. Progressive paralysis develops over months to years, typically leading to respiratory failure. Median survival is 2–5 years post-diagnosis. Treatment aims to slow progression, manage symptoms, and maintain quality of life.
Diagnosis is clinical, confirmed by electromyography (EMG) and magnetic resonance imaging (MRI) ruling out alternative diagnoses. Disease-modifying therapy includes riluzole, which modestly extends survival by 2–3 months through glutamate antagonism, and edaravone, an antioxidant approved in some countries, showing marginal benefit in rapidly progressing disease. Symptomatic management is multidisciplinary: physiotherapy maintains joint mobility and prevents contractures; speech and language therapy addresses dysarthria and dysphagia. Nutritional support includes high-calorie diet, tube feeding (percutaneous endoscopic gastrostomy, PEG) when swallowing deteriorates. Non-invasive ventilation (BiPAP) supports respiratory function, extending survival and improving quality of life. Psychological support addresses emotional burden. Riluzole combined with multidisciplinary care represents standard management.
Herbal remedies, antioxidant supplementation (vitamin E, coenzyme Q10, creatine), and dietary approaches emphasising Mediterranean or plant-based nutrition reflect speculative neuroprotection; robust evidence is absent. Acupuncture may provide symptomatic relief (pain, cramping) with variable outcomes. Traditional Chinese medicine and other complementary approaches are explored by some patients, though clinical validation in ALS is lacking.
Stem cell therapy is studied for ALS, with bone marrow-derived stem cells, neural stem cells, and mesenchymal stem cells investigated in multiple clinical trials. Proposed mechanisms include neuroprotection through secreted factors, reduction of motor neurone apoptosis, and promotion of motor neurone survival. Phase 2 trials have been conducted, with mixed outcomes; some patients report slowing of progression or modest functional stabilisation, whilst others show no benefit. Clinical efficacy is not yet established, and protocols remain experimental. Candidate assessment focuses on early to mid-stage ALS with documented disease progression, typically within 2–3 years of diagnosis.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| EMG & MRI diagnostic confirmation | Standard | Strong | €800–€1,500 | Low | Immediate |
| Riluzole (disease-modifying) | Standard | Moderate | €600–€1,200/month | Low | Ongoing |
| Edaravone (antioxidant therapy) | Standard | Moderate | €2,000–€5,000/month | Medium | Ongoing |
| Non-invasive ventilation (BiPAP) | Standard | Strong | €2,000–€6,000 | Low | 2–4 weeks |
| Antioxidant & supplement therapy | Alternative | Limited | €50–€150/month | Low | Ongoing |
| Acupuncture for symptom relief | Alternative | Limited | €70–€140 per session | Low | Immediate |
| Neural stem cell therapy | Regenerative | Investigational | €25,000–€50,000 | Medium | 4–8 weeks |
| Multidisciplinary rehabilitation team | Standard | Strong | €100–€400/month | Low | Ongoing |
Riluzole extends median survival by approximately 2–3 months and slows functional decline. Benefit is modest; it does not halt disease progression. Early initiation and combination with comprehensive care optimises outcomes.
BiPAP is initiated when forced vital capacity (FVC) declines to 50% of predicted or when symptoms of nocturnal hypoventilation appear (morning headaches, sleep disruption). Early introduction improves compliance and quality of life.
PEG is recommended when swallowing becomes unsafe or inadequate to maintain nutrition, typically mid-stage disease. Early insertion, before significant weight loss, optimises tolerability and nutritional outcomes. It does not extend survival but supports quality of life.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite